These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Morgellons disease, or antipsychotic-responsive delusional parasitosis, in an HIV patient: beliefs in the age of the Internet. Freudenreich O; Kontos N; Tranulis C; Cather C Psychosomatics; 2010; 51(6):453-7. PubMed ID: 21051675 [No Abstract] [Full Text] [Related]
6. Disorder or delusion? Living with Morgellons disease. Simpson L; Baier M J Psychosoc Nurs Ment Health Serv; 2009 Aug; 47(8):36-41. PubMed ID: 19681520 [TBL] [Abstract][Full Text] [Related]
7. Morgellons disease: experiences of an integrated multidisciplinary dermatology team to achieve positive outcomes. Mohandas P; Bewley A; Taylor R J Dermatolog Treat; 2018 Mar; 29(2):208-213. PubMed ID: 28665169 [TBL] [Abstract][Full Text] [Related]
8. Variable clinical presentations of secondary delusional infestation: an experience of six cases from a psychodermatology clinic. Altunay IK; Ates B; Mercan S; Demirci GT; Kayaoglu S Int J Psychiatry Med; 2012; 44(4):335-50. PubMed ID: 23885516 [TBL] [Abstract][Full Text] [Related]
10. The challenge of Morgellons disease: A patient with clinicopathologic correlation. Caputo V; Bonoldi E; Citterio A; Rongioletti F Clin Dermatol; 2022; 40(6):686-690. PubMed ID: 35905899 [TBL] [Abstract][Full Text] [Related]
11. [Morgellons syndrome: a disease transmitted via the media]. Misery L Ann Dermatol Venereol; 2013 Jan; 140(1):59-62. PubMed ID: 23328363 [No Abstract] [Full Text] [Related]
12. Psychosis, ivermectin toxicity, and "Morgellons disease". DeBonis K; Pierre JM Psychosomatics; 2011; 52(3):295-6. PubMed ID: 21565604 [No Abstract] [Full Text] [Related]
13. Delusional Infestation: State of the Art. Vulink NC Acta Derm Venereol; 2016 Aug; 96(217):58-63. PubMed ID: 27282746 [TBL] [Abstract][Full Text] [Related]
14. Morgellons: contested illness, diagnostic compromise and medicalisation. Fair B Sociol Health Illn; 2010 May; 32(4):597-612. PubMed ID: 20149149 [TBL] [Abstract][Full Text] [Related]
15. Choosing the appropriate pharmacotherapy for Morgellons disease: an expert perspective. Balogh EA; Beuerlein KG; Feldman SR Expert Opin Pharmacother; 2022 Apr; 23(5):527-530. PubMed ID: 35076344 [No Abstract] [Full Text] [Related]
17. Successful treatment of Morgellons disease with pimozide therapy. Reid EE; Lio PA Arch Dermatol; 2010 Oct; 146(10):1191-3. PubMed ID: 20956673 [No Abstract] [Full Text] [Related]
18. Intravenous immunoglobulin for refractory cutaneous dermatomyositis: a retrospective analysis from an academic medical center. Femia AN; Eastham AB; Lam C; Merola JF; Qureshi AA; Vleugels RA J Am Acad Dermatol; 2013 Oct; 69(4):654-7. PubMed ID: 24034377 [No Abstract] [Full Text] [Related]
19. The quinacrine experience in a population of patients with cutaneous lupus erythematosus and dermatomyositis. Mittal L; Werth VP J Am Acad Dermatol; 2017 Aug; 77(2):374-377. PubMed ID: 28711090 [No Abstract] [Full Text] [Related]